OTCMKTS:HLUYY H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis $22.00 -0.01 (-0.02%) (As of 08/9/2022) Add Compare Share Share Today's Range$22.00▼$24.0050-Day Range$22.00▼$22.0052-Week Range$10.00▼$31.55Volume7,500 shsAverage Volume1,758 shsMarket Capitalization$21.91 billionP/E Ratio25.00Dividend Yield0.91%Price TargetN/A Stock AnalysisStock Analysis Get H. Lundbeck A/S alerts: Email Address Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.Read More HLUYY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLUYY Stock News HeadlinesJuly 26 at 5:32 AM | americanbankingnews.comH. Lundbeck A/S (OTCMKTS:HLUYY) Stock Crosses Below 50 Day Moving Average of $22.00July 25 at 2:24 PM | msn.com'Bounce back': How a long-time RAGBRAI rider fulfilled his dream alongside his daughterJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...July 24 at 3:41 AM | msn.comWhitney Rydbeck, Friday the 13th and M*A*S*H actor, dead at 79July 18, 2024 | americanbankingnews.comH. Lundbeck A/S (OTCMKTS:HLUYY) Shares Pass Below 50 Day Moving Average of $22.00May 17, 2024 | morningstar.comH. Lundbeck AS Class A HLUN AMay 2, 2024 | msn.comBluey’s Big Play coming to Buddy Holly Hall in AugustApril 26, 2024 | seekingalpha.comGIFLF Grifols, S.A.July 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...April 22, 2024 | msn.comNew Hampshire's 'Kid Conservationist' joins 'Jennifer Hudson Show' for Earth DayApril 16, 2024 | finance.yahoo.comH. Lundbeck A/S (LDBB.F)April 15, 2024 | msn.com‘Vanished’: 25 years since Nathan Edberg’s vehicle was found abandoned in Vadnais Heights, search for answers continuesMarch 25, 2024 | fool.comH. Lundbeck A/s (OTC: HLUYY)February 23, 2024 | investing.comH Lundbeck A/S ADR (HLUYY)February 11, 2024 | msn.comWWE: Becky Lynch gives fans a preview of what to expect from her bookJanuary 19, 2024 | msn.comA Chilling New Twist in the Lindbergh Baby Mystery Could Actually Flip the VerdictAugust 23, 2023 | wsj.comH. Lundbeck A/S Cl AAugust 11, 2023 | msn.com‘Finding W.H. Hudson’ Review: The Enigmatic BirdmanSee More Headlines Receive HLUYY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2015Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private Households Sub-IndustryN/A Current SymbolOTCMKTS:HLUYY CUSIPN/A CIKN/A Webwww.lundbeck.com Phone(453) 630-1311Fax45-3630-1940Employees5,348Year Founded1915Profitability EPS (Most Recent Fiscal Year)$0.88 Trailing P/E Ratio25.00 Forward P/E Ratio10.48 P/E GrowthN/ANet Income$209.69 million Net Margins6.74% Pretax Margin7.83% Return on Equity13.74% Return on Assets7.16% Debt Debt-to-Equity Ratio0.32 Current Ratio1.15 Quick Ratio0.71 Sales & Book Value Annual Sales$2.59 billion Price / Sales8.45 Cash Flow$3.36 per share Price / Cash Flow6.54 Book Value$14.60 per share Price / Book1.51Miscellaneous Outstanding Shares995,741,000Free FloatN/AMarket Cap$21.91 billion OptionableNot Optionable Beta0.68 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Deborah Dunsire M.D. (Age 60)Pres & CEO Comp: $7.16MMr. Jacob Tolstrup (Age 50)Exec. VP of Commercial Operations & Chief Commercial Officer Comp: $888.17kMr. Lars Bang (Age 60)Exec. VP of Product Devel. & Supply Comp: $915.5kDr. Per Johan Luthman (Age 63)Exec. VP of R&D Comp: $901.84kMr. Bjorn R. MogensenSr. VP Group Fin.Dr. Tarek Samad Ph.D.Sr. VP & Head of ResearchMr. Palle Holm OlesenChief Specialist & VP of Investor RelationsMs. Elise Hauge (Age 55)Exec. VP of People & Communication Mr. Ole Chrintz (Age 64)Sr. VP of International Markets Mr. Keld Flintholm Jorgensen (Age 51)Exec. VP of Corp. Strategy & Bus. Devel. More ExecutivesKey CompetitorsShin-Etsu ChemicalOTCMKTS:SHECYIberdrolaOTCMKTS:IBDRYITOCHUOTCMKTS:ITOCYGlencoreOTCMKTS:GLNCYVinciOTCMKTS:VCISYView All Competitors Should I Buy H. Lundbeck A/S Stock? HLUYY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in H. Lundbeck A/S: Recent positive clinical trial results for a new drug, indicating potential future revenue growth. Strong financial performance with consistent revenue growth and profitability. Expansion into emerging markets, providing opportunities for market share growth. Current stock price is undervalued compared to industry peers, presenting a good buying opportunity. Robust pipeline of innovative products in the neuroscience sector, promising future growth potential. Cons Investors should be bearish about investing in H. Lundbeck A/S for these reasons: Regulatory challenges in key markets could impact product approvals and market access. Competition from generic drug manufacturers may put pressure on pricing and market share. Currency exchange rate fluctuations could affect international revenue and profitability. Dependency on a few key products for a significant portion of revenue, posing risks in case of product failures. Recent management changes or restructuring activities may introduce uncertainties in the company's strategic direction. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 28, 2024. Please send any questions or comments about these H. Lundbeck A/S pros and cons to contact@marketbeat.com. HLUYY Stock Analysis - Frequently Asked Questions How have HLUYY shares performed this year? H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00. View the best growth stocks for 2024 here. How were H. Lundbeck A/S's earnings last quarter? H. Lundbeck A/S (OTCMKTS:HLUYY) posted its quarterly earnings data on Wednesday, November, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.16. The company earned $547.05 million during the quarter, compared to analyst estimates of $514.82 million. H. Lundbeck A/S had a net margin of 6.74% and a trailing twelve-month return on equity of 13.74%. Does H. Lundbeck A/S have any subsidiaries? H. Lundbeck A/S subsidiaries include Alder BioPharmaceuticals, and Prexton Therapeutics. How do I buy shares of H. Lundbeck A/S? Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HLUYY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H. Lundbeck A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share H. Lundbeck A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
